Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.88 |
| ▸ | POLB | P06746 | 2/20 | 0.81 |
| ▸ | DHFR | P00374 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2315638 | 0.88 | MEN1 (0.83) | MEN1KMT2APOLBDHFRALDH1A1 | |
| SCHEMBL28987743 | 0.82 | MEN1 (0.71) | MEN1KMT2APOLB | |
| SCHEMBL31441369 | 0.82 | MEN1 (0.71) | MEN1KMT2APOLB | |
| SCHEMBL28596594 | 0.81 | MEN1 (0.70) | MEN1KMT2APOLB | |
| SCHEMBL31196722 | 0.81 | SMN1; SMN2 (0.70) | MEN1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL5863348 | 0.80 | KDM4E (0.81) | MEN1KMT2APOLBDHFRALDH1A1 | |
| SCHEMBL26758120 | 0.80 | MEN1 (0.67) | MEN1KMT2APOLBSMN1; SMN2 | |
| Water SCHEMBL27728020 | 0.79 | MEN1 (0.66) | MEN1KMT2APOLB | |
| SCHEMBL7425922 | 0.78 | MEN1 (0.67) | MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL12789340 | 0.78 | MEN1 (0.55) | MEN1KMT2APOLBDHFRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030120-B2 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | OHKURA NAOTO (JP) | 2004-11-11 | — | — | US | disclosed |
| US-6777414-B1 | INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| EP-1180514-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2002-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | APOB, NCEH1, LIPC | MEN1 4072/4885KMT2A 2580/4885POLB 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.